Search

Your search keyword '"Douglas A. Johnson"' showing total 890 results

Search Constraints

Start Over You searched for: Author "Douglas A. Johnson" Remove constraint Author: "Douglas A. Johnson" Topic business.industry Remove constraint Topic: business.industry
890 results on '"Douglas A. Johnson"'

Search Results

2. Cutaneous adverse events caused by immune checkpoint inhibitors

3. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection

4. A vaccination update for rheumatologists—SARS‐CoV‐2, influenza and herpes zoster

5. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma

6. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

7. Diagnosis and management of atopic dermatitis

8. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

9. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

10. Cutaneous Melanoma: Management of Melanoma Brain Metastases and Molecular Testing

11. Endocrine toxicities of immune checkpoint inhibitors

12. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021

13. Supportive care for new cancer therapies

14. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma

15. Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety

16. Advanced Melanoma

17. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

18. Respiratory Candida in Patients with Bronchitis, Mucus Plugging, and Atelectasis

19. MEK inhibitors in non-V600 BRAF mutations and fusions

20. Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19

21. Encouraging Multiculturalism and Diversity within Organizational Behavior Management

22. Cancer immunotherapy–related adverse events: causes and challenges

23. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors

24. Pandemic printing: a novel 3D‐printed swab for detecting <scp>SARS</scp> ‐CoV‐2

25. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

26. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

27. Telehealth during the coronavirus disease 2019 pandemic: Rapid expansion of telehealth outpatient use during a pandemic is possible if the programme is previously established

28. Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition

29. Navigating shifting waters: rapid response to change in the era of COVID‐19

30. The Effects of Feedback Modality on Performance

31. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

32. Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma

33. The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer

34. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

35. Neurologic complications of immune checkpoint inhibitors

36. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

37. 812 Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells

38. 239 Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study

39. Acquired acrodermatitis enteropathica from a ketogenic diet

40. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer

41. High levels of psychosocial distress among Australian frontline healthcare workers during the COVID-19 pandemic: a cross-sectional survey

42. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy

43. Risk stratification of individuals undergoing surgery after COVID-19 recovery

44. Hospitalisation, morbidity and outcomes associated with respiratory syncytial virus compared with influenza in adults of all ages

46. Hospitalisation, morbidity and outcomes associated with respiratory syncytial virus compared to influenza in adults of all ages

49. Challenges with Providing Hospice Care for Patients Undergoing Long-Term Dialysis

50. Impact of point-of-care ultrasound on the hospital length of stay for internal medicine inpatients with cardiopulmonary diagnosis at admission

Catalog

Books, media, physical & digital resources